Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. (Form: SC 13D/A, Received: 01/29/2018 13:26:13)
 

 SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC  20549

SCHEDULE 13D
(Rule 13d-101)

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3) 1
 
Esperion Therapeutics, Inc.
(Name of Issuer)
 
Common Stock, $.001 par value
(Title of Class of Securities)
 
29664W105
(CUSIP Number)
 
 
Domain Associates, LLC
Ropes & Gray LLP
 
 
One Palmer Square
1211 Avenue of the Americas
 
 
Princeton, NJ  08542
New York, NY 10036
 
 
Attn: Lisa A. Kraeutler
Attn: Morri H. Weinberg, Esq.
 
 
Tel: (609) 683-5656
Tel: (212) 596-9000
 
 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
 
 January 24, 2018
 (Date of Event Which Requires Filing of This Statement)
 
 
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.   

Note .  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.



1 The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ).
 
 

 
CUSIP No. 29664W105

 
 
1.
 
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
(VOLUNTARY)
 
EIN No.:
Domain Partners VII, L.P.
 
2.
 
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
 
(a) 
(b) 
 
3.
 
SEC USE ONLY
 
4.
 
SOURCE OF FUNDS
Not Applicable
 
5.
 
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS
IS  REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
 
 
6.
 
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
 
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
 
 
7.
 
 
SOLE VOTING POWER
1,101,080
 
8.
 
SHARED VOTING POWER
-0-
 
9.
 
 
SOLE DISPOSITIVE POWER
1,101,080
 
10.
 
SHARED DISPOSITIVE POWER
-0-
 
11.
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,101,080
 
12.
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES
 
 
13.
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.2%
 
14.
 
TYPE OF REPORTING PERSON
PN
 
 

 
2

 
CUSIP No. 29664W105

 
 
1.
 
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
(VOLUNTARY)
 
EIN No.:
DP VII Associates, L.P.
 
2.
 
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
 
(a) 
(b) 
 
3.
 
SEC USE ONLY
 
4.
 
SOURCE OF FUNDS
Not Applicable
 
5.
 
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS
IS  REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
 
 
6.
 
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
 
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
 
 
7.
 
 
SOLE VOTING POWER
15,329
 
8.
 
SHARED VOTING POWER
-0-
 
9.
 
 
SOLE DISPOSITIVE POWER
15,329
 
10.
 
SHARED DISPOSITIVE POWER
-0-
 
11.
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
15,329
 
12.
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES
 
 
13.
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
Less than 0.1%
 
14.
 
TYPE OF REPORTING PERSON
PN





3

 
CUSIP No. 29664W105

 
 
1.
 
NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
(VOLUNTARY)
 
EIN No.:
Domain Associates, LLC
 
2.
 
 
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
 
 
(a) 
(b) 
 
3.
 
SEC USE ONLY
 
4.
 
SOURCE OF FUNDS
Not Applicable
 
5.
 
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS
IS  REQUIRED PURSUANT TO ITEM 2(d) or 2(e)
 
 
6.
 
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
 
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
 
 
7.
 
 
SOLE VOTING POWER
21,471
 
8.
 
SHARED VOTING POWER
-0-
 
9.
 
 
SOLE DISPOSITIVE POWER
21,471
 
10.
 
SHARED DISPOSITIVE POWER
-0-
 
11.
 
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
21,471
 
12.
 
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES
 
 
13.
 
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
Less than 0.1%
 
14.
 
TYPE OF REPORTING PERSON
OO
 
 

 

4

 
CUSIP No. 29664W105

 
AMENDMENT NO. 3 TO SCHEDULE 13D (FINAL AMENDMENT)

Reference is hereby made to the statement on Schedule 13D filed with the Securities and Exchange Commission (the "Commission") by the Reporting Persons with respect to the Common Stock of the Issuer on October 30, 2014, Amendment No. 1 thereto filed on March 25, 2015, and Amendment No. 2 thereto filed on December 8, 2017 (as so amended, the "Schedule 13D".) Terms defined in the Schedule 13D are used herein as so defined.

Item 5.                            Interest in Securities of the Issuer.

Item 5(a) of the Schedule 13D is hereby amended and restated as follows:

The information requested by this paragraph is incorporated herein by reference to the cover pages to this Amendment No. 3 to Schedule 13D. Ownership percentages are based on 26,197,749 shares of Common Stock outstanding as of November 1, 2017, as reported in the Issuer's Report on Form 10-Q for the period ended September 30, 2017 filed with the Commission on November 7, 2017,

In addition, Nicole Vitullo directly beneficially owns 3,117 shares of Common Stock, as well as (i) 5,000 shares of Common Stock issuable upon exercise of a presently-exercisable option to purchase 5,000 shares of Common Stock, at an exercise price of $14.42 per share, which was granted on May 15, 2014 and expires on May 15, 2024, (ii) 8,000 shares of Common Stock issuable upon exercise of a presently-exercisable option to purchase 8,000 shares of Common Stock, at an exercise price of $107.74 per share, which was granted on May 14, 2015 and expires on May 14, 2025and (iii) 8,000 shares of Common Stock issuable upon exercise of a presently-exercisable option to purchase 8,000 shares of Common Stock, at an exercise price of $17.75 per share, which was granted on June 9, 2016 and expires on June 9, 2026.

Item 5(c) of the Schedule 13D is hereby amended and restated as follows:

On January 24, 2018, DP VII distributed in kind 850,000 shares of Common Stock pro rata to its partners, including 8,500 shares to OPSA VII.  Also on January 24, 2018, DP VII and DP VIIA net exercised 70,042 Warrants and 1,193 Warrants, respectively. The exercise price of the Warrants was $6.99 per share and the fair market value on the date of exercise was $71.82, which was the price used to calculate the number of shares used to pay the exercise price.

On January 25, 2018 DP VIIA sold 11,674 shares of Common Stock in open market transactions, at a weighted average price of $71.79 per share.

On January 26, 2018, OPSA VII distributed 8,500 shares of Common Stock pro rata to its members, which represented all of the Common Stock directly held by OPSA VII.

Item 5(e) of the Schedule 13D is hereby amended and restated as follows:
The Reporting Persons ceased to beneficially own more than five percent of the Common Stock on January 24, 2018.




5

 
CUSIP No. 29664W105

SIGNATURES

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated:  January 29, 2018

 
DOMAIN PARTNERS VII, L.P.
 
 
 
By:
/s/ Lisa A. Kraeutler
 
   
Attorney-in-Fact
 
 
DP VII ASSOCIATES, L.P.
 
 
 
By:
/s/ Lisa A. Kraeutler
 
   
Attorney-in-Fact
 
 
DOMAIN ASSOCIATES, LLC
 
 
 
By:
/s/ Lisa A. Kraeutler
 
   
Attorney-in-Fact
 

 
 

 
6